Jun 03, 2018
Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma
May 17, 2018
Forty Seven, Inc. to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association (EHA)
May 16, 2018
Forty Seven, Inc. to Present Clinical Data on 5F9, its First-in-Class CD47 Antibody, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 03, 2018
Forty Seven, Inc. Granted Fast Track Designation for 5F9 for the Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Apr 30, 2018
Forty Seven Inc. Appoints Ian T. Clark to Board of Directors
Apr 03, 2018
Forty Seven, Inc. Appoints Ann D. Rhoads as Chief Financial Officer
Feb 20, 2018
Forty Seven Inc. Appoints Kristine M. Ball to Board of Directors
Feb 06, 2018
Forty Seven Inc. to Present at the 2018 BIO CEO & Investor Conference
Jan 11, 2018
Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer
Jan 11, 2018
Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer
Jan 04, 2018
Forty Seven Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 06, 2017
Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Oct 17, 2017
Forty Seven Inc. Completes $75 Million Series B Financing